Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.07
PRGO's Cash to Debt is ranked lower than
95% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. PRGO: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
PRGO' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 0.22 Max: 18.37
Current: 0.07
0
18.37
Equity to Asset 0.52
PRGO's Equity to Asset is ranked lower than
65% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PRGO: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
PRGO' s Equity to Asset Range Over the Past 10 Years
Min: 0.34  Med: 0.54 Max: 0.75
Current: 0.52
0.34
0.75
Interest Coverage 2.91
PRGO's Interest Coverage is ranked lower than
84% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. PRGO: 2.91 )
Ranked among companies with meaningful Interest Coverage only.
PRGO' s Interest Coverage Range Over the Past 10 Years
Min: 5.48  Med: 9.37 Max: 11.67
Current: 2.91
5.48
11.67
F-Score: 5
Z-Score: 1.32
M-Score: -2.48
WACC vs ROIC
6.16%
2.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 9.73
PRGO's Operating margin (%) is ranked higher than
53% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. PRGO: 9.73 )
Ranked among companies with meaningful Operating margin (%) only.
PRGO' s Operating margin (%) Range Over the Past 10 Years
Min: -32.27  Med: 13.14 Max: 19.18
Current: 9.73
-32.27
19.18
Net-margin (%) -0.61
PRGO's Net-margin (%) is ranked lower than
75% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. PRGO: -0.61 )
Ranked among companies with meaningful Net-margin (%) only.
PRGO' s Net-margin (%) Range Over the Past 10 Years
Min: -34.47  Med: 7.32 Max: 12.66
Current: -0.61
-34.47
12.66
ROE (%) -0.32
PRGO's ROE (%) is ranked lower than
71% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. PRGO: -0.32 )
Ranked among companies with meaningful ROE (%) only.
PRGO' s ROE (%) Range Over the Past 10 Years
Min: -62.64  Med: 15.81 Max: 25.93
Current: -0.32
-62.64
25.93
ROA (%) -0.18
PRGO's ROA (%) is ranked lower than
69% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. PRGO: -0.18 )
Ranked among companies with meaningful ROA (%) only.
PRGO' s ROA (%) Range Over the Past 10 Years
Min: -28.65  Med: 5.83 Max: 11.14
Current: -0.18
-28.65
11.14
ROC (Joel Greenblatt) (%) 31.48
PRGO's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. PRGO: 31.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRGO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -70.75  Med: 33.63 Max: 53.39
Current: 31.48
-70.75
53.39
Revenue Growth (3Y)(%) 6.00
PRGO's Revenue Growth (3Y)(%) is ranked higher than
50% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. PRGO: 6.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRGO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.5  Med: 7.50 Max: 16.6
Current: 6
-5.5
16.6
EBITDA Growth (3Y)(%) 7.90
PRGO's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. PRGO: 7.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRGO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -25  Med: 25.80 Max: 42.5
Current: 7.9
-25
42.5
EPS Growth (3Y)(%) -21.30
PRGO's EPS Growth (3Y)(%) is ranked lower than
82% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. PRGO: -21.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRGO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.2  Med: 25.80 Max: 210.7
Current: -21.3
-66.2
210.7
» PRGO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

PRGO Guru Trades in Q2 2015

Richard Perry 336,000 sh (New)
Louis Moore Bacon 80,000 sh (New)
Mario Gabelli 1,550 sh (New)
Joel Greenblatt 6,903 sh (New)
George Soros 92,653 sh (New)
Daniel Loeb 600,000 sh (New)
Jeremy Grantham 2,900 sh (New)
Steve Mandel 375,924 sh (New)
Kyle Bass 836,593 sh (New)
Eric Mindich 1,444,815 sh (New)
Jim Simons 634,367 sh (+1712.06%)
Paul Tudor Jones 60,245 sh (+804.04%)
Louis Moore Bacon 20,000 sh (unchged)
Robert Bruce 9,926 sh (unchged)
Ron Baron Sold Out
Alan Fournier Sold Out
John Keeley 29,113 sh (-5.27%)
Ruane Cunniff 1,466,859 sh (-13.65%)
Vanguard Health Care Fund 3,129,532 sh (-18.83%)
David Rolfe 892,486 sh (-39.93%)
Ken Fisher 233,870 sh (-49.28%)
Steven Cohen 15,600 sh (-85.82%)
» More
Q3 2015

PRGO Guru Trades in Q3 2015

John Paulson 2,938,500 sh (New)
Paul Singer 451,896 sh (New)
Eric Mindich 2,986,851 sh (+106.73%)
Richard Perry 650,000 sh (+93.45%)
George Soros 113,921 sh (+22.95%)
Vanguard Health Care Fund 3,409,132 sh (+8.93%)
Ruane Cunniff 1,469,515 sh (+0.18%)
Robert Bruce 9,926 sh (unchged)
Eric Mindich 300,000 sh (unchged)
Mario Gabelli 1,550 sh (unchged)
Jeremy Grantham Sold Out
Daniel Loeb Sold Out
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Louis Moore Bacon Sold Out
Steve Mandel Sold Out
Kyle Bass Sold Out
John Keeley 28,101 sh (-3.48%)
Ken Fisher 217,661 sh (-6.93%)
David Rolfe 815,674 sh (-8.61%)
Jim Simons 321,608 sh (-49.30%)
Paul Tudor Jones 1,764 sh (-97.07%)
» More
Q4 2015

PRGO Guru Trades in Q4 2015

Ron Baron 261,138 sh (New)
Jerome Dodson 90,000 sh (New)
Louis Moore Bacon 14,364 sh (New)
Paul Tudor Jones 6,400 sh (+262.81%)
David Rolfe 2,113,216 sh (+159.08%)
Robert Bruce 9,926 sh (unchged)
Mario Gabelli Sold Out
Richard Perry Sold Out
George Soros Sold Out
Ken Fisher 215,946 sh (-0.79%)
Ruane Cunniff 1,447,149 sh (-1.52%)
John Paulson 2,662,000 sh (-9.41%)
John Keeley 24,726 sh (-12.01%)
Jim Simons 131,308 sh (-59.17%)
Paul Singer 177,915 sh (-60.63%)
Eric Mindich 843,318 sh (-71.77%)
Vanguard Health Care Fund 170,000 sh (-95.01%)
» More
Q1 2016

PRGO Guru Trades in Q1 2016

Manning & Napier Advisors, Inc 877,730 sh (New)
Jerome Dodson 130,000 sh (+44.44%)
Ken Fisher 265,942 sh (+23.15%)
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Perrigo Co PLC

David Rolfe Comments on Perrigo - Apr 15, 2016

Perrigo (NYSE:PRGO)

Perrigo was a bottom performance contributor in the quarter, as the company reported a miss in its Branded Consumer Healthcare (BCH) segment. Management attributed the miss to execution issues and dedicated themselves to solving these problems over the coming quarters. We are willing to be patient; in the meantime, as we think that Perrigo’s core, private label OTC business is unique and should remain a healthy and sustainable source of internal capital.

Perrigo’s BCH segment was established after closing on the acquisition of Omega Pharma (Belgium) in March 2015. Mylan’s hostile bid for Perrigo was launched a few weeks later, and did not conclude until mid-November. We think that Perrigo’s BCH execution issues are understandable (if not predictable), as management was admittedly distracted by fending off Mylan’s hostile bid for the Company during much of 2015. Over the next several quarters, we expect BCH to post improved results, as it is better integrated with Perrigo’s corporate planning cycle.

From David Rolfe (Trades, Portfolio)'s Wedgewood Partners 1st Quarter 2016 Client Letter.

Check out David Rolfe latest stock trades

Baron Funds Comments on Perrigo Company Plc - Jan 26, 2016

We re-established an investment in Perrigo Company Plc (NYSE:PRGO) during the quarter. Perrigo is a leading global over-the-counter (OTC) consumer goods and specialty pharmaceutical manufacturer. The company is the world’s largest manufacturer of store brand OTC health care products (such as store brand ibuprofen, the active ingredient in Advil), which are sold in virtually all leading U.S. drug retailers, including Walgreens and CVS. We previously owned Perrigo in the Fund. In early 2015, the company became the subject of a hostile takeover bid by Mylan N.V., a large manufacturer of generic pharmaceuticals. After Perrigo shareholders rejected Mylan’s proposal, Perrigo’s stock fell to a price that we believed was attractive in light of the company’s growth potential, competitive advantages and impressive management team.



We think Perrigo can generate sustainable mid-to-high single digit organic revenue growth, driven by a trend favoring store brand OTC drugs over national brands. Perrigo management estimates its business saves consumers more than $7.5 billion annually in their health care spending ($1 savings for every person in the world). This is because store brand OTC drugs are comparable in quality and effectiveness to the national brands but cost significantly less. Store brand OTC drugs also generate higher gross margins for retailers.



We think Perrigo’s business should also benefit as more prescription drugs move to OTC status. This trend is being driven by branded drug manufacturers seeking to capture ongoing product sales after the products lose patent protection. Perrigo has dominant market share in the store brand OTC drug business. We believe the company’s competitive advantages include long-standing customer relationships, low cost manufacturing and an ability to mass customize thousands of products and support retailers in marketing their store brands.



Perrigo’s management team has a strong record of creating shareholder value. They have a disciplined approach to deploying capital with a focus on meeting return on invested capital hurdles. We think management will continue to pursue acquisitions which should add to the company’s growth. These acquisitions could include products that Perrigo could add to its distribution network at high incremental margin, products in new categories, or companies in new geographies. In addition, in its defense against the Mylan hostile takeover attempt, Perrigo management committed to several shareholder value creating initiatives that are expected to add to earnings over the next few years.



From Baron Funds' Baron Asset Fund commentary for fourth quarter 2015.



Check out Ron Baron latest stock trades

Wedgewood Partners Comments on Perrigo - Jan 18, 2016

Perrigo (NYSE:PRGO) is another position that we added to during the quarter. We had previously pared positions at materially higher levels after Mylan’s hostile bid for Perrigo became public information. Upon the recent expiration of the hostile offer, shares traded down to valuation levels not seen since 2008-2009, at which time we added back to our position. Management has guided to solid future growth, driven by the Company’s leading position in manufacturing and distributing private label over-the-counter (OTC) drugs to U.S. retailers, as well as its relatively new and rapidly expanding European OTC platform.



From Wedgewood Partners' fourth quarter 2015 client letter.



Check out David Rolfe latest stock trades

Keeley Mid-Cap Value Fund Comments on Perrigo Co. - Sep 17, 2015

Another strong contributor during the quarter was Perrigo Co. (NYSE:PRGO) which climbed over 11 percent and added 24 basis points of performance to the Fund. The generic drug maker entered into an agreement with GlaxoSmithKline PLC to acquire a portfolio of over-the-counter drugs. Perrigo has already make acquisitions in the OTC business and this deal should allow them to capture an even larger share of the significant OTC market in Europe.



From the Keeley Mid-Cap Value Fund Second Quarter 2015 Commentary.



Check out John Keeley latest stock trades

Top Ranked Articles about Perrigo Co PLC

Ackman to Testify About Valeant Before Senate Valeant names Joseph Papa of Perrigo as new CEO
Activist investor Bill Ackman (Trades, Portfolio) will testify before the Senate Special Committee on Aging Wednesday regarding his involvement with Valeant Pharmaceuticals (NYSE:VRX), along with outgoing CEO Michael Pearson, just a day after Joseph Papa of Perrigo (NYSE:PRGO) was announced as Pearson’s replacement. Read more...
David Rolfe Comments on Perrigo Guru stock highlight
Perrigo (NYSE:PRGO)

Perrigo was a bottom performance contributor in the quarter, as the company reported a miss in its Branded Consumer Healthcare (BCH) segment. Management attributed the miss to execution issues and dedicated themselves to solving these problems over the coming quarters. We are willing to be patient; in the meantime, as we think that Perrigo’s core, private label OTC business is unique and should remain a healthy and sustainable source of internal capital.

Perrigo’s BCH segment was established after closing on the acquisition of Omega Pharma (Belgium) in March 2015. Mylan’s hostile bid for Perrigo was launched a few weeks later, and did not conclude until mid-November. We think that Perrigo’s BCH execution issues are understandable (if not predictable), as management was admittedly distracted by fending off Mylan’s hostile bid for the Company during much of 2015. Over the next several quarters, we expect BCH to post improved results, as it is better Read more...
David Rolfe Nearly Doubles His Stake in Perrigo Rolfe adds 1,297,542 shares of Perrigo to Wedgewood Partners' portfolio
Missouri native David Rolfe (Trades, Portfolio) became passionately interested with investing in 1984 after he signed up for an investments class at the University of Missouri, St Louis. Rolfe entered the class called Investments 334 and began to fall in love with the thought of investing in the stock market. He became so interested that he and another student alongside his professor Dr. Ken Lock founded “The Student Investment Club.” The club started out as a paper portfolio and it still continues to run today, competing against schools across the U.S. Read more...
Baron Funds Comments on Perrigo Company Plc Guru stock highlight
We re-established an investment in Perrigo Company Plc (NYSE:PRGO) during the quarter. Perrigo is a leading global over-the-counter (OTC) consumer goods and specialty pharmaceutical manufacturer. The company is the world’s largest manufacturer of store brand OTC health care products (such as store brand ibuprofen, the active ingredient in Advil), which are sold in virtually all leading U.S. drug retailers, including Walgreens and CVS. We previously owned Perrigo in the Fund. In early 2015, the company became the subject of a hostile takeover bid by Mylan N.V., a large manufacturer of generic pharmaceuticals. After Perrigo shareholders rejected Mylan’s proposal, Perrigo’s stock fell to a price that we believed was attractive in light of the company’s growth potential, competitive advantages and impressive management team. Read more...
Wedgewood Partners Comments on Perrigo Guru stock highlight
Perrigo (NYSE:PRGO) is another position that we added to during the quarter. We had previously pared positions at materially higher levels after Mylan’s hostile bid for Perrigo became public information. Upon the recent expiration of the hostile offer, shares traded down to valuation levels not seen since 2008-2009, at which time we added back to our position. Management has guided to solid future growth, driven by the Company’s leading position in manufacturing and distributing private label over-the-counter (OTC) drugs to U.S. retailers, as well as its relatively new and rapidly expanding European OTC platform. Read more...
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Guru also active in energy, agricultural companies
Health care stocks are the most heavily weighted stocks in Kyle Bass (Trades, Portfolio)’ portfolio so it is no surprise that health care-related stocks would hold prominent positions in his third-quarter transactions. Read more...
John Paulson Increases Holding in Teva Pharmaceutical A look at the hedge fund manager's recent trades
John Paulson is an American hedge fund manager and billionaire who founded the New York-based investment management firm Paulson & Co. in 1994. Paulson has most recently added 18,000,000 shares of Teva Pharmaceutical Industries (NYSE:TEVA), a 746.48% increase in his holding. Paulson & Co. have also bought 2,938,500 shares of Perrigo Co. PLC (NYSE:PRGO) and 7,007,346 shares of CIT Group Inc. (NYSE:CIT). Read more...
John Paulson Keeps Gold, Buys Drug Manufacturers in Q3 Investor increases health care bet as M&A activity abounds in sector
John Paulson (Trades, Portfolio) made billions in the housing crash and employs an event-driven arbitrage investing strategy at his firm Paulson & Co., where he manages about $19.5 billion. Outsized bets tend to make the manager’s returns vary to extremes. For instance, in recent years his funds lost as much as 36% for 2014, after gaining as much as 46% in 2013. Read more...
Keeley Mid-Cap Value Fund Comments on Perrigo Co. Guru stock highlight
Another strong contributor during the quarter was Perrigo Co. (NYSE:PRGO) which climbed over 11 percent and added 24 basis points of performance to the Fund. The generic drug maker entered into an agreement with GlaxoSmithKline PLC to acquire a portfolio of over-the-counter drugs. Perrigo has already make acquisitions in the OTC business and this deal should allow them to capture an even larger share of the significant OTC market in Europe. Read more...
Alan Fournier Sells Nine Stakes in Second Quarter Divestitures are the most Fournier has recorded in years
Alan Fournier (Trades, Portfolio) founded Pennant Capital Management in 2001 and manages Pennant Master Fund, Pennant Windward Master Fund, Broadway Gate Master Fund Ltd.,and Pennant General Partner LLC. Today Pennant Capital Management is worth around $4 billion. Read more...

Ratios

vs
industry
vs
history
Forward P/E 9.68
PRGO's Forward P/E is ranked higher than
77% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. PRGO: 9.68 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 38.26
PRGO's Price/Owner Earnings (ttm) is ranked lower than
57% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. PRGO: 38.26 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PRGO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.37  Med: 24.25 Max: 83.43
Current: 38.26
11.37
83.43
P/B 1.39
PRGO's P/B is ranked higher than
77% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. PRGO: 1.39 )
Ranked among companies with meaningful P/B only.
PRGO' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 3.01 Max: 5.96
Current: 1.39
1.39
5.96
P/S 2.60
PRGO's P/S is ranked higher than
52% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. PRGO: 2.60 )
Ranked among companies with meaningful P/S only.
PRGO' s P/S Range Over the Past 10 Years
Min: 0.93  Med: 2.55 Max: 6.17
Current: 2.6
0.93
6.17
PFCF 15.47
PRGO's PFCF is ranked higher than
69% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. PRGO: 15.47 )
Ranked among companies with meaningful PFCF only.
PRGO' s PFCF Range Over the Past 10 Years
Min: 10.67  Med: 24.87 Max: 83.99
Current: 15.47
10.67
83.99
POCF 13.03
PRGO's POCF is ranked higher than
66% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. PRGO: 13.03 )
Ranked among companies with meaningful POCF only.
PRGO' s POCF Range Over the Past 10 Years
Min: 8.42  Med: 18.76 Max: 30.33
Current: 13.03
8.42
30.33
EV-to-EBIT 37.26
PRGO's EV-to-EBIT is ranked lower than
76% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. PRGO: 37.26 )
Ranked among companies with meaningful EV-to-EBIT only.
PRGO' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.8  Med: 19.80 Max: 52.4
Current: 37.26
-6.8
52.4
EV-to-EBITDA 23.81
PRGO's EV-to-EBITDA is ranked lower than
66% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. PRGO: 23.81 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRGO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8  Med: 15.30 Max: 33.4
Current: 23.81
-8
33.4
Shiller P/E 42.06
PRGO's Shiller P/E is ranked higher than
57% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. PRGO: 42.06 )
Ranked among companies with meaningful Shiller P/E only.
PRGO' s Shiller P/E Range Over the Past 10 Years
Min: 41.84  Med: 93.81 Max: 228.94
Current: 42.06
41.84
228.94
Current Ratio 1.10
PRGO's Current Ratio is ranked lower than
86% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. PRGO: 1.10 )
Ranked among companies with meaningful Current Ratio only.
PRGO' s Current Ratio Range Over the Past 10 Years
Min: 1.1  Med: 2.37 Max: 4.05
Current: 1.1
1.1
4.05
Quick Ratio 0.76
PRGO's Quick Ratio is ranked lower than
86% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. PRGO: 0.76 )
Ranked among companies with meaningful Quick Ratio only.
PRGO' s Quick Ratio Range Over the Past 10 Years
Min: 0.76  Med: 1.32 Max: 3.56
Current: 0.76
0.76
3.56
Days Inventory 86.88
PRGO's Days Inventory is ranked higher than
66% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. PRGO: 86.88 )
Ranked among companies with meaningful Days Inventory only.
PRGO' s Days Inventory Range Over the Past 10 Years
Min: 92.5  Med: 99.08 Max: 108.46
Current: 86.88
92.5
108.46
Days Sales Outstanding 81.40
PRGO's Days Sales Outstanding is ranked lower than
56% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. PRGO: 81.40 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRGO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 57.67  Med: 65.00 Max: 84.05
Current: 81.4
57.67
84.05
Days Payable 62.61
PRGO's Days Payable is ranked lower than
57% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. PRGO: 62.61 )
Ranked among companies with meaningful Days Payable only.
PRGO' s Days Payable Range Over the Past 10 Years
Min: 50.89  Med: 64.83 Max: 70.25
Current: 62.61
50.89
70.25

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.53
PRGO's Dividend Yield is ranked lower than
84% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. PRGO: 0.53 )
Ranked among companies with meaningful Dividend Yield only.
PRGO' s Dividend Yield Range Over the Past 10 Years
Min: 0.22  Med: 0.39 Max: 1.23
Current: 0.53
0.22
1.23
Dividend Payout 0.48
PRGO's Dividend Payout is ranked lower than
67% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. PRGO: 0.48 )
Ranked among companies with meaningful Dividend Payout only.
PRGO' s Dividend Payout Range Over the Past 10 Years
Min: 0.07  Med: 0.13 Max: 0.42
Current: 0.48
0.07
0.42
Dividend Growth (3y) 12.60
PRGO's Dividend Growth (3y) is ranked higher than
61% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. PRGO: 12.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
PRGO' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 8.00 Max: 49.8
Current: 12.6
0
49.8
Forward Dividend Yield 0.60
PRGO's Forward Dividend Yield is ranked lower than
81% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. PRGO: 0.60 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.97
PRGO's Yield on cost (5-Year) is ranked lower than
71% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. PRGO: 0.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
PRGO' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.4  Med: 0.71 Max: 2.25
Current: 0.97
0.4
2.25
3-Year Average Share Buyback Ratio -7.30
PRGO's 3-Year Average Share Buyback Ratio is ranked lower than
64% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.30 vs. PRGO: -7.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PRGO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.8  Med: 0.20 Max: 1.7
Current: -7.3
-9.8
1.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.09
PRGO's Price/Projected FCF is ranked higher than
83% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. PRGO: 1.09 )
Ranked among companies with meaningful Price/Projected FCF only.
PRGO' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.60 Max: 2.42
Current: 1.09
0.95
2.42
Price/Median PS Value 1.02
PRGO's Price/Median PS Value is ranked higher than
61% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. PRGO: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
PRGO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.23  Med: 0.54 Max: 2.18
Current: 1.02
0.23
2.18
Price/Graham Number 6.82
PRGO's Price/Graham Number is ranked lower than
89% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.09 vs. PRGO: 6.82 )
Ranked among companies with meaningful Price/Graham Number only.
PRGO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.15  Med: 2.11 Max: 12.59
Current: 6.82
1.15
12.59
Earnings Yield (Greenblatt) (%) 2.73
PRGO's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. PRGO: 2.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRGO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.9  Med: 5.00 Max: 8.8
Current: 2.73
1.9
8.8
Forward Rate of Return (Yacktman) (%) 12.64
PRGO's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. PRGO: 12.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PRGO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.8  Med: 6.10 Max: 35.7
Current: 12.64
1.8
35.7

More Statistics

Revenue(Mil) $5350
EPS $ -0.25
Beta0.73
Short Percentage of Float6.95%
52-Week Range $94.82 - 200.96
Shares Outstanding(Mil)143.20

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue(Mil) 5,985 6,423 6,966 6,452
EPS($) 9.18 9.93 10.99 8.97
EPS without NRI($) 9.18 9.93 10.99 8.97

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:PIG.Germany, PRGO.Israel,
Perrigo Co PLC was incorporated under the laws of Ireland on June 28, 2013. The Company develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients. The Company is a manufacturer of OTC healthcare products for the store brand market. The Company has five reportable segments, aligned by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences. The Consumer Healthcare segment is the store brand manufacturer of OTC pharmaceutical products. Its product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation and animal health; secondary product categories include feminine hygiene, diabetes care and dermatological care. The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, and vitamin, mineral and dietary supplement products to retailers, distributors and consumers in the U.S., Canada, Mexico and China. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs for the U.S. market. it encompasses an array of topical dosage forms such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The Company develops, manufactures, and markets API used by the generic drug industry and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. The manufacturing of these API occurs in Israel. Its competitors in the U.S. Consumer Healthcare market are Dr. Reddy's Laboratories, Ltd., Actavis Inc., Ranbaxy Inc., PL Developments, Nipro Corporation, and LNK International, Inc. Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber) and Danone Baby Nutrition. Tysabri competes with Avonex, marketed by Biogen Idec; Betaseron, marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the U.S. The Company is subject to various environmental laws and regulations.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK